Combination immunotherapy and chemotherapy for advanced bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have not received any prior cancer treatment for advanced or locally advanced bile duct cancer
- Your cancer is confirmed by biopsy or pathology and cannot be surgically removed
- You have at least one measurable tumor that can be tracked on imaging
- Your overall health is good enough for treatment (ECOG performance status 0 or 1)
- Your heart, liver, and kidney function are adequate to safely receive treatment
- You are 18 to 75 years old and willing to use effective contraception during and 3 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This study tests a combination of freezing the tumor (cryoablation), an investigational immunotherapy (QL1706), and a targeted therapy pill (lenvatinib) for people with advanced bile duct cancer that has progressed after initial treatment. The goal is to see if this new combination can help control the cancer and improve outcomes.
This trial tests a new combination of an oncolytic virus plus lenvatinib and toripalimab (immunotherapy drugs) compared with the standard chemotherapy FOLFOX for advanced bile duct or gallbladder cancer. The goal is to see if the new combination helps people whose cancer has progressed after one line of treatment.
This trial tests a combination of four drugs for people with advanced bile duct or gallbladder cancer that has spread. The drugs target HER2, a protein on some cancer cells, and may help shrink tumors or slow their growth.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, for people with advanced bile duct or gallbladder cancer that has grown after previous treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two immunotherapy drugs, chemotherapy, and a targeted therapy to shrink bile duct or gallbladder cancers that are advanced but might be removable with surgery. The goal is to see if this approach can make surgery possible and improve outcomes.
Hear when a new Biliary Tract Cancer (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.